相关实验视频
Updated: Jan 13, 2026

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
5.3K
药物重新定位在多克索鲁比诱导的心脏毒性保护中的作用
Marija Kosić1, Vladislav Pajović1, Mirjana Jovanović2
1Institute of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
International journal of molecular sciences
|October 29, 2025
概括
德克索鲁比化疗可能会导致严重的心脏损伤. 这篇评论探讨了重定向药物,如抗抑郁药paroxetine,以预防或治疗这种多克索鲁比诱导的心脏毒性.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多克索鲁比 (DOX) 是各种癌症的重要化疗剂.
- doxorubicin 诱导的心脏毒性 (DIC) 是一种严重的,可能致命的副作用.
- 目前用于管理DIC的策略有限,机制尚未完全阐明.
研究的目的:
- 审查关于用于多克索鲁比诱导心脏毒性 (DIC) 的药物重用现有证据.
- 为了突出帕洛克塞的潜在心脏保护作用,帕洛克塞是一种已知的抗抑郁药.
主要方法:
- 对调查DIC药物重定向的研究的文献综述.
- 专注于与选择性血清素再吸收抑制剂 (SSRI) 及其心脏保护潜力相关的证据.
主要成果:
- 药物重新定位为缓解DIC提供了一个有希望的途径.
- 帕洛西丁显示出潜在的心脏保护作用,需要进一步调查.
结论:
- 药物重新定位,特别是使用诸如帕洛素之类的药物,可能为DIC提供新的治疗策略.
- 需要进一步的研究来验证用于预防和治疗DIC的重定向药物的疗效和安全性.
相关概念视频
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Cardiomyopathy II: Dilated Cardiomyopathy
457
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
457
Cardiopulmonary Resuscitation IV: Pharmacological Management
639
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
639
Cardiomyopathy V: Interprofessional Care
331
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
331
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K

